Immune and Autoimmune Enteropathies

Vol. 64, No. 1, 2006

View or print article as PDF (308 KB)

Journal Home

Paper

Immune and Autoimmune Enteropathies
Philip M. Sherman^a, Ernest Cutz^a, Olivier Goulet^b

^aHospital for Sick Children, University of Toronto, Toronto, Ont., Canada;
^bGroupe Hospitalier Necker-Enfant Malade, Paris, France

Address of Corresponding Author

Annales Nestlé (English ed.) 2006;64:7-13 (DOI: 10.1159/000086495)

Key Words

Diarrhea, children and infants
Enteropathy, immune and autoimmune
IPEX syndrome
Autoimmunity

Abstract

Autoimmune enteropathy characteristically presents in infancy with protracted diarrhea. Underlying disorders of immune function, including regulatory T cells, must be excluded. Treatment options include nutritional rehabilitation, immune suppression, and, in select cases, bone marrow transplant.

References

1.: Sherman PM, Mitchell DJ, Cutz E: Neonatal enteropathies: defining the causes of protracted diarrhea of infancy. J Pediatr Gastroenterol Nutr 2004;38:16-26.
2.: Camilleri M: Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist. Clin Gastroenterol Hepatol 2004;2:198-206.
3.: Schiller LR: Chronic diarrhea. Gastroenterology 2004;127:287-293.
4.: Bhutta ZA, Ghishan F, Lindley K, Memon IA, Mittal S, Rhoads JM: Persistent and chronic diarrhea and malabsorption: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004;39(suppl 2):S711-S716.
5.: Hill ID, Dirks MH, Liptak GS, et al: Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005;40:1-19.
6.: Cutz E, Rhoads JM, Drumm B, et al: Microvillus inclusion disease: an inherited defect of brush-border assembly and differentiation. N Engl J Med 1989;320:646-651.
7.: Phillips AD, Schmitz J: Familial microvillous atrophy: a clinicopathological survey of 23 cases. J Pediatr Gastroenterol Nutr 1992;14:380-396.
8.: Reifen RM, Cutz E, Griffiths AM, et al: Tufting enteropathy: a newly recognized clinicopathological entity associated with refractory diarrhea in infants. J Pediatr Gastroenterol Nutr 1994;18:379-385.
9.: Patey N, Scoazec JY, Cuenod-Jabri B, et al: Distribution of cell adhesion molecules in infants with intestinal epithelial dysplasia (tufting enteropathy). Gastroenterology 1997;113:833-843.
10.: Pirisi-Hauck NC, Foss H-D, Baier J, Kurunczi S: Simultaneous occurrence of autoimmune enteropathy and recurrent deep vein thrombosis. J Pediatr Gastroenterol Nutr 2000;30:324-329.
11.: Carroccio A, Volta U, Di Prima L, et al: Autoimmune enteropathy and colitis in an adult patient. Dig Dis Sci 2003;48:1600-1606.
12.: Cutz E, Sherman PM, Davidson GP: Enteropathies associated with protracted diarrhea of infancy: clinicopathological features, cellular and molecular mechanisms. Pediatr Pathol Lab Med 1997;17:335-368.
13.: Murch SH, Fertleman CR, Rodrigues C, et al: Autoimmune enteropathy with distinct mucosal features in T-cell activation deficiency: the contribution of T cells to the mucosal lesion. J Pediatr Gastroenterol Nutr 1999;28:393-399.
14.: Cuenod B, Brousse N, Goulet O, et al: Classification of intractable diarrhea of infancy using clinical and immunohistological criteria. Gastroenterology 1990;99:1037-1043.
15.: King C, Lic A, Koelsch K, Sarvetnick N: Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-277.
16.: Mirakian R, Richardson A, Milla PJ, et al: Protracted diarrhoea of infancy: evidence in support of an autoimmune variant. Br Med J (Clin Res Ed) 1986;293:1132-1136.
17.: Colletti RB, Guillot AP, Rosen S, et al: Autoimmune enteropathy and nephropathy with circulating anti-epithelial cell antibodies. J Pediatr 1991;118:858-864.
18.: Kobayashi I, Imamura K, Yamada M, et al. A 75-kD autoantigen recognized by sera from patients with X-linked autoimmune enteropathy associated with nephropathy. Clin Exp Immunol 1998;111:527-531.
19.: Kobayashi I, Imamura K, Kubota M, et al: Identification of an autoimmune enteropathy-related 75-kilodalton antigen. Gastroenterology 1999;117:823-830.
20.: Ishikawa S, Kobayashi I, Hamada J-I, et al: Interaction of MCC2, a novel homologue of MCC tumor suppressor, with PDZ-domain protein AIE-75. Gene 2001;267:101-110.
21.: Martin-Villa JM, Regueiro JR, De Juan D, et al: T-lymphocyte dysfunctions occurring together with apical gut epithelial cell autoantibodies. Gastroenterology 1991;101:390-397.
22.: Moore L, Xu X, Davidson G, et al: Autoimmune enteropathy with anti-goblet cell antibodies. Hum Pathol 1995;26:1162-1168.
23.: Shaoul R, Hong D, Okada Y, Cutz E, Marcon M: Lineage development in a patient without goblet, Paneth and enteroendocrine cells, a clue for intestinal epithelial differentiation. Pediatr Res 2005, in press.
24.: Yang Q, Berminham A, Finegold MJ, et al: Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 2001;294:2155-2158.
25.: Goulet O, Seidman E: Gastrointestinal manifestations of immunodeficiency. 1. Primary immunodeficiency diseases; in Walker W, Goulet O, Kleinman R, Sherman P, Shneider B, Sanderson I (eds): Pediatric Gastrointestinal Disease, ed 4. Philadelphia, B.C. Decker, 2004, pp 707-733.
26.: Arniaz-Villena A, Timon M, Corell A, et al: Primary immunodeficiency caused by mutations in the gene encoding the CD3-gamma subunit of the T-lymphocyte receptor. N Engl J Med 1992;327:529-533.
27.: Kaitila I, Savilahti E, Ormala T: Autoimmune enteropathy in Schimke immunoosseous dysplasia. Am J Med Genet 1998;77:427-430.
28.: Stormon M, Friedman J, King S, Cutz E, Furuya KN: An unusual case of diarrhea in Schimke immuno-osseous dysplasia. J Pediatr Gastroenterol Nutr 2002;35:369-371.
29.: Bennett CL, Christie J, Ramsdell F, et al: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-21.
30.: Ochs HD, Ziegler SF, Torgerson TR: FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005;203:156-164.
31.: Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor FOXP3. Science 2003;299:1057-1061.
32.: Hori S, Sakaguchi S: Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004;6:745-751.
33.: Fontenot JD, Gavin MA, Rudensky AY: FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
34.: Bakke AC, Purtzer MZ, Wildin RS: Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). Clin Exp Immunol 2004;137:373-378.
35.: Eisenbarth GS, Gottlieb PA: Autoimmune polyendocrine syndromes. N Engl J Med 2004;350:2068-2079.
36.: Ruemmele FM, Brousse N, Goulet O: Autoimmune enteropathy: molecular concepts. Curr Opin Gastroenterol 2004;20:587-591.
37.: Nieves DS, Phipps RP, Pollock SJ, et al: Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Arch Dermatol 2004;140:466-472.
38.: Patel DD: Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse. J Clin Invest 2001;107:155-157.
39.: Lo CW, Walker WA: Chronic protracted diarrhea of infancy: a nutritional disease. Pediatrics 1983;72:786-800.
40.: Seidman EG, Lacaille F, Russo P, et al: Successful treatment of autoimmune enteropathy with cyclosporine. J Pediatr 1990;117:929-932.
41.: Sanderson IR, Phillips AD, Spencer J, Walker-Smith JA: Response to autoimmune enteropathy to cyclosporin A therapy. Gut 1991;32:1421-1425.
42.: Bousvaros A, Leichtner AM, Book L, et al: Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996;111:237-243.
43.: Bindl L, Torgerson T, Perroni L, Youssef N, Ochs HD, Goulet O, Ruemmele FM: Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syn drome). J Pediatr 2005, in press.
44.: Quiroz-Tejeira RE, Ament ME, Vargas JH: Induction of remission in a child with autoimmune enteropathy using mycophenolate mofetil. J Pediatr Gastroenterol Nutr 2003;36:482-485.
45.: Oliva-Hemper MM, Loeb DM, Abraham SC, et al: Remission of severe autoimmune enteropathy after treatment with high-dose cyclophosphamide. J Pediatr Gastroenterol Nutr 2003;36:639-643.
46.: Vanderhoof JA, Young RJ: Autoimmune enteropathy in a child: response to infliximab therapy. J Pediatr Gastroenterol Nutr 2002;34:312-316.
47.: Baud O, Goulet O, Canioni D, et al: Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked sydrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001;344:1758-1762.
48.: Collins SM, McHugh K, Croitoru K, et al: The establishment of a national tissue bank for inflammatory bowel disease research in Canada. Can J Gastroenterol 2003;17:107-109.

Author Contacts

Philip M. Sherman, MD, FRCPC
Gastroenterology and Nutrition, Room 8409
Hospital for Sick Children, 555 University Avenue
Toronto, Ont. M5G 1X8 (Canada)
Tel. +1 416 813 7734, Fax +1 416 813 6531, E-Mail philip.sherman@sickkids.ca

Article Information

Number of Print Pages : 7
Number of Figures : 3, Number of Tables : 0, Number of References : 48

Publication Details

Annales Nestlé (English ed.)

Vol. 64, No. 1, Year 2006 (Cover Date: 2006)

Journal Editor: Editorial Committee
ISSN: 0517-8606 (print), 1661-4011 (Online)

For additional information: http://www.karger.com/ANE

Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

	© 2009 S. Karger AG, Basel
	Last update: 22/3/2006